-
公开(公告)号：KR101200189B1
公开(公告)日：2012-11-13
申请号：KR1020070076188
申请日：2007-07-30
Applicant: 재단법인서울대학교산학협력재단 , 중앙대학교 산학협력단
Abstract: 본 발명은 면역침강법을 활용한 결합 단백질들의 탐색방법에 관한 것으로, 특정단백질과 결합하는 새로운 단백질을 발굴하는 방법을 제시함에 있어 종래의 면역침강법을 보완하여, 한 번의 면역침강실험으로 여러 종류의 단백질군들과의 결합여부를 확인할 수 있는 방법에 관한 것이다. 이를 위하여 본 발명은 미끼단백질에 결합하는 단백질들의 탐색방법에 있어서, 미끼단백질과의 결합여부를 확인하고 싶은 단백질을 조합하여 항체 풀 세트를 구성하고 각각의 항체의 정보를 얻어 기준이 되는 룰러를 마련하고, 상기 항체 풀세트를 사용해 미끼단백질과의 웨스턴 블랏을 시행하여 결과를 얻고, 상기 웨스턴 블랏의 결과를 상기 항체 풀 세트의 룰러와 비교하여 결합여부를 확인하는 과정을 포함한다.
면역침강, SDS-PAGE, 웨스턴 블랏-
公开(公告)号：KR101145061B1
公开(公告)日：2012-05-11
申请号：KR1020070076217
申请日：2007-07-30
Applicant: 재단법인서울대학교산학협력재단 , 중앙대학교 산학협력단
Abstract: A pharmaceutical composition is provided to increase transcriptional activity of p53 and cell death by hindering analysis of p53 by MDM2 and to have anticancer effect suppressing dysplasia and carcinogenesis of cell. A pharmaceutical composition shows anticancer effect by including p19Ras protein as active component, uniting p19Ras protein with p53 protein and increasing activity of the p53 protein. The p19Ras protein is indicated as amino acid sequence of a sequence listing sequence number 1. The cancer is breast cancer, ovarian cancer, liver cancer, lung cancer, colon carcinoma or prostate cancer. An activity of the p53 protein is increased by hindering ubiquitination of p53 by MDM2.
-
3.发明公开ｐ19ｒａｓ 유전자를 포함하는 발현벡터 또는 ｐ19ｒａｓ단백질을 유효성분으로 하는 암의 예방 또는 치료용 약학적조성물 无效用于治疗或预防包含含有P19RAS基因或P19RAS蛋白作为有效成分的表达载体的癌症的药物组合物
公开(公告)号：KR1020090111726A
公开(公告)日：2009-10-27
申请号：KR1020080037461
申请日：2008-04-22
Applicant: 중앙대학교 산학협력단 , 재단법인서울대학교산학협력재단
CPC classification number: A61K38/1709 , A61K48/00 , C07K14/47 , C12N15/66
Abstract: PURPOSE: A pharmaceutical composition for preventing and treating cancer, which contains an expression vector containing p19ras gene or p19ras protein is provided to suppress abnormal proliferation. CONSTITUTION: A pharmaceutical composition for preventing or treating cancer contains an expression vector of p19ras gene or p19ras protein. The p19ras gene is denoted by sequence of the sequence number 1. The cancer is a cancer in which NSE is overexpressed.
Abstract translation: 目的：提供含有含有p19ras基因或p19ras蛋白质的表达载体的用于预防和治疗癌症的药物组合物，以抑制异常增殖。 构成：用于预防或治疗癌症的药物组合物含有p19ras基因或p19ras蛋白的表达载体。 p19ras基因以序列号1的序列表示。癌症是NSE过表达的癌症。
-
公开(公告)号：KR1020090111728A
公开(公告)日：2009-10-27
申请号：KR1020080037463
申请日：2008-04-22
Applicant: 중앙대학교 산학협력단 , 재단법인서울대학교산학협력재단
CPC classification number: A61K38/1709 , C07K14/4703 , Y10S514/912
Abstract: PURPOSE: A pharmaceutical composition for preventing and treating NRL-mediated eye disease is provided to control NRL activation. CONSTITUTION: A pharmaceutical composition for preventing and treating NRL-mediated eye diseases contains JNK1 as an active ingredient. The JNK1 has an amino acid of the sequence number 1. The NRL has an amino acid of the sequence number 3. The pharmaceutical composition contains a recombinant vector as an active ingredient with a polynucleotide encoding JNK1 or promoter.
Abstract translation: 目的：提供用于预防和治疗NRL介导的眼病的药物组合物以控制NRL活化。 构成：用于预防和治疗NRL介导的眼部疾病的药物组合物含有JNK1作为活性成分。 JNK1具有序列号1的氨基酸.NNL具有序列号3的氨基酸。药物组合物含有作为活性成分的重组载体，其具有编码JNK1或启动子的多核苷酸。
-
公开(公告)号：KR1020090012416A
公开(公告)日：2009-02-04
申请号：KR1020070076217
申请日：2007-07-30
Applicant: 재단법인서울대학교산학협력재단 , 중앙대학교 산학협력단
Abstract: A pharmaceutical composition is provided to increase transcriptional activity of p53 and cell death by hindering analysis of p53 by MDM2 and to have anticancer effect suppressing dysplasia and carcinogenesis of cell. A pharmaceutical composition shows anticancer effect by including p19Ras protein as active component, uniting p19Ras protein with p53 protein and increasing activity of the p53 protein. The p19Ras protein is indicated as amino acid sequence of a sequence listing sequence number 1. The cancer is breast cancer, ovarian cancer, liver cancer, lung cancer, colon carcinoma or prostate cancer. An activity of the p53 protein is increased by hindering ubiquitination of p53 by MDM2.
Abstract translation: 提供药物组合物，通过抑制MDM2对p53的分析和抑制细胞发育不良和致癌作用具有抗癌作用，增加p53的转录活性和细胞死亡。 药物组合物通过包括p19Ras蛋白作为活性成分显示抗癌作用，将p19Ras蛋白与p53蛋白质结合并增加p53蛋白的活性。 p19Ras蛋白被表示为序列表序列号1的氨基酸序列。癌症是乳腺癌，卵巢癌，肝癌，肺癌，结肠癌或前列腺癌。 通过抑制MDM2对p53的泛素化，p53蛋白的活性增加。
-
Patent Agency Ranking
公开(公告)号：KR1020090012407A
公开(公告)日：2009-02-04
申请号：KR1020070076188
申请日：2007-07-30
Applicant: 재단법인서울대학교산학협력재단 , 중앙대학교 산학협력단
Abstract: A method for searching proteins uniting with bait protein is provided to confirm bond with various kinds of protein families through one immunoprecipitation experiment. A method for searching proteins uniting with bait protein comprises steps of: assembling protein which wants to confirm bond with the bait protein and making antibody full set; implementing Western blot with the bait protein using the antibody full set and obtaining a result; comparing a result of the Western blot with a ruler of the antibody full set and confirming whether bond is performed or not. A method for manufacturing the ruler comprises steps of: loading cell lysate of cell strain for expressing the bait protein and separating protein within the cell lysate by using SDS-PAGE; assembling the protein which wants to confirm bond with the bait protein and making the antibody full set; implementing Western blot using antibody of the antibody full set; and comparing results with a size marker and linearizing and indicating it.
Abstract translation: 提供一种搜索与诱饵蛋白结合的蛋白质的方法，通过一次免疫沉淀实验确认与各种蛋白质家族的结合。 搜索与诱饵蛋白结合的蛋白质的方法包括以下步骤：组装蛋白质，其需要确认与诱饵蛋白质的结合并使抗体完整; 使用抗体全套实施诱饵蛋白的Western印迹并获得结果; 将Western印迹的结果与抗体全集的标尺进行比较，并确认是否进行结合。 制造尺的方法包括以下步骤：通过使用SDS-PAGE，加载用于表达诱饵蛋白的细胞株的细胞裂解物和细胞裂解物内的蛋白质分离; 组装需要确认与诱饵蛋白质结合并使抗体完整的蛋白质; 使用抗体全抗体实施蛋白质印迹; 并将结果与大小标记进行比较，并进行线性化和指示。
-
公开(公告)号：KR1020110036291A
公开(公告)日：2011-04-07
申请号：KR1020090093870
申请日：2009-10-01
Applicant: 중앙대학교 산학협력단 , 서울대학교산학협력단
CPC classification number: A61K38/1709 , C07K14/4705 , C07K2319/00 , G01N33/5008 , G01N2500/00
Abstract: PURPOSE: A pharmaceutical composition containing TIP60 is provided to induce transcription activity of a target gene promoter and to relieve or treat retinal diseases. CONSTITUTION: A pharmaceutical composition for relieving or treating retinal diseases contains TIP60 as an active ingredient. TIP60 binds to NRL protein. TIP60 contains chromo domain and histone aceytltransferase domain. The activation of TIP60 is measured by increasing transcription activity of NRL protein.
Abstract translation: 目的：提供含有TIP60的药物组合物，以诱导靶基因启动子的转录活性，并缓解或治疗视网膜疾病。 构成：用于缓解或治疗视网膜疾病的药物组合物含有TIP60作为活性成分。 TIP60结合NRL蛋白。 TIP60含有染色体结构域和组蛋白乙酰转移酶结构域。 通过增加NRL蛋白的转录活性来测量TIP60的活化。
-
公开(公告)号：KR1020110028082A
公开(公告)日：2011-03-17
申请号：KR1020090086003
申请日：2009-09-11
Applicant: 중앙대학교 산학협력단 , 서울대학교산학협력단
IPC: G01N33/563 , C12Q1/68 , A61P25/28
CPC classification number: C12Q1/6897 , G01N33/5008 , G01N33/6896 , G01N2500/00
Abstract: PURPOSE: A neurodegenerative disease-related CP2 transcription factor is provided to treat neurodegenerative diseases without side effects. CONSTITUTION: A kit for diagnosing neurodegenerative diseases comprises a nucleotide sequence of CP2 of sequence number 1, complementary sequence of the nucleotide, nucleotide fragment, or an antibody or aptamer which specifically binds to CP2 protein of sequence number 2. The kit is a microarray. A method for screening a material which prevents or treats neurodegenerative diseases comprises: a step of contacting a sample to cells containing CP2 gene or protein; and a step of measuring expression level of CP2 gene, CP2 protein level, or CP2 protein activity.
Abstract translation: 目的：提供神经退行性疾病相关的CP2转录因子，用于治疗无副作用的神经变性疾病。 构成：用于诊断神经变性疾病的试剂盒包括序列号1的CP2的核苷酸序列，核苷酸，核苷酸片段的互补序列，或特异性结合序列号2的CP2蛋白的抗体或适体。该试剂盒是微阵列。 用于筛选预防或治疗神经变性疾病的材料的方法包括：使样品与含有CP2基因或蛋白质的细胞接触的步骤; 测定CP2基因，CP2蛋白水平或CP2蛋白活性的表达水平。
-
公开(公告)号：KR101152289B1
公开(公告)日：2012-06-08
申请号：KR1020090093870
申请日：2009-10-01
Applicant: 중앙대학교 산학협력단 , 서울대학교산학협력단
Abstract: 본발명은 TIP60을유효성분으로포함하는망막질환개선또는치료용조성물및 망막질환치료제의스크리닝방법에관한것이다. 본발명은망막질환에서 NRL과 TIP60의상호결합및 이를통한 NRL 단백질의전사활성화를규명한최초의보고이다. 본발명에서, TIP60은 NRL에직접적으로결합하여 NRL 단백질의전사활성을증가시켜타겟유전자의프로모터(예컨대, 로돕신프로모터)의전사활성화를유도함으로써망막질환개선또는치료에이용될수 있다. 또한, 본발명은망막질환(특히, 망막색소변성증)을치료하는데있어서 TIP60 단백질의조절을통한신약개발및 치료방법에기초적인자료를제공한다.
-
公开(公告)号：KR101130552B1
公开(公告)日：2012-03-23
申请号：KR1020090086003
申请日：2009-09-11
Applicant: 중앙대학교 산학협력단 , 서울대학교산학협력단
IPC: G01N33/563 , C12Q1/68 , A61P25/28
Abstract: 본 발명은 신경퇴행성 질환에 관여하는 CP2 전사인자에 관한 것이다. 본 발명은 다운 스트림(downstream)에 위치하는 발병 유전자를 전사 기작 측면에서 조절한다는 특이성이 있으며, 이는 종래의 APP 유전자나 이에 관련된 효소들의 억제방법에서 야기되는 심각한 신경발생 장애와 같은 부작용 없이 치료가 가능하다. 또한, 본 발명은 신경 퇴행성 질환(특히, 알츠하이머병)을 치료하는데 있어서 CP2 전사인자의 조절을 통한 신약 개발 및 치료방법에 기초적인 자료를 제공한다.
CP2, 알츠하이머, 진단, 키트, 스크리닝
-
-
-
-
-
-
-
-
-
Search Results
12
records
(took 0.027 seconds)
